OBJECTIVE: To determine the prevalence of Hispanic/Latino adults with diabetes who meet target hemoglobin A1c, blood pressure (BP), and low-density-lipoprotein cholesterol (LDL-C) recommendations, and angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blocker (ARB) and statin medication use by heritage and sociodemographic and diabetes-related characteristics. METHODS: Data were cross-sectional, collected between 2008 and 2011, and included adults age 18 to 74 years who reported a physician diagnosis of diabetes in the Hispanic Community Health Study/Study of Latinos (N = 2,148). Chi-square tests compared the prevalence of hemoglobin A1c, BP, and LDL-C targets and ACE/ARB and statin use across participant characteristics. Predictive margins regression was used to determine the prevalence adjusted for sociodemographic characteristics. RESULTS: The overall prevalence of A1c <7.0% (53 mmol/mol), BP <130/80 mm Hg, and LDL-C <100 mg/dL was 43.0, 48.7, and 36.6%, respectively, with 8.4% meeting all three targets. Younger adults aged 18 to 39 years with diabetes were less likely to have A1c <7.0% (53 mmol/mol) or LDL-C <100 mg/dL compared to those aged 65 to 74 years; younger adults were more likely to have BP <130/80 mm Hg (P<.05 for all). Individuals of Mexican heritage were significantly less likely to have A1c <7.0% (53 mmol/mol) compared to those with Cuban heritage, but they were more likely to have BP <130/80 mm Hg compared to those with Dominican, Cuban, or Puerto Rican heritage (P<.05 for all); there was no difference in LDL-C by heritage. Overall, 38.2% of adults with diabetes were taking a statin, and 50.5% were taking ACE/ARB medications. CONCLUSION: Hemoglobin A1c, BP, and LDL-C control are suboptimal among Hispanic/Latinos with diabetes living in the U.S. With 8.4% meeting all three recommendations, substantial opportunity exists to improve diabetes control in this population. ABBREVIATIONS: A1c = hemoglobin A1c; ABC = hemoglobin A1c, blood pressure, low-density-lipoprotein cholesterol; ACE = angiotensin-converting enzyme; ADA = American Diabetes Association; ARB = angiotensin receptor blocker; BMI = body mass index; BP = blood pressure; CHD = coronary heart disease; CVD = cardiovascular disease; HCHS/SOL = Hispanic Community Health Study/Study of Latinos; LDL-C = low-density-lipoprotein cholesterol; NHANES = National Health and Nutrition Examination Survey; PAD = peripheral artery disease.
OBJECTIVE: To determine the prevalence of Hispanic/Latino adults with diabetes who meet target hemoglobin A1c, blood pressure (BP), and low-density-lipoprotein cholesterol (LDL-C) recommendations, and angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blocker (ARB) and statin medication use by heritage and sociodemographic and diabetes-related characteristics. METHODS: Data were cross-sectional, collected between 2008 and 2011, and included adults age 18 to 74 years who reported a physician diagnosis of diabetes in the Hispanic Community Health Study/Study of Latinos (N = 2,148). Chi-square tests compared the prevalence of hemoglobin A1c, BP, and LDL-C targets and ACE/ARB and statin use across participant characteristics. Predictive margins regression was used to determine the prevalence adjusted for sociodemographic characteristics. RESULTS: The overall prevalence of A1c <7.0% (53 mmol/mol), BP <130/80 mm Hg, and LDL-C <100 mg/dL was 43.0, 48.7, and 36.6%, respectively, with 8.4% meeting all three targets. Younger adults aged 18 to 39 years with diabetes were less likely to have A1c <7.0% (53 mmol/mol) or LDL-C <100 mg/dL compared to those aged 65 to 74 years; younger adults were more likely to have BP <130/80 mm Hg (P<.05 for all). Individuals of Mexican heritage were significantly less likely to have A1c <7.0% (53 mmol/mol) compared to those with Cuban heritage, but they were more likely to have BP <130/80 mm Hg compared to those with Dominican, Cuban, or Puerto Rican heritage (P<.05 for all); there was no difference in LDL-C by heritage. Overall, 38.2% of adults with diabetes were taking a statin, and 50.5% were taking ACE/ARB medications. CONCLUSION: Hemoglobin A1c, BP, and LDL-C control are suboptimal among Hispanic/Latinos with diabetes living in the U.S. With 8.4% meeting all three recommendations, substantial opportunity exists to improve diabetes control in this population. ABBREVIATIONS: A1c = hemoglobin A1c; ABC = hemoglobin A1c, blood pressure, low-density-lipoprotein cholesterol; ACE = angiotensin-converting enzyme; ADA = American Diabetes Association; ARB = angiotensin receptor blocker; BMI = body mass index; BP = blood pressure; CHD = coronary heart disease; CVD = cardiovascular disease; HCHS/SOL = Hispanic Community Health Study/Study of Latinos; LDL-C = low-density-lipoprotein cholesterol; NHANES = National Health and Nutrition Examination Survey; PAD = peripheral artery disease.
Authors: Lisa M Lavange; William D Kalsbeek; Paul D Sorlie; Larissa M Avilés-Santa; Robert C Kaplan; Janice Barnhart; Kiang Liu; Aida Giachello; David J Lee; John Ryan; Michael H Criqui; John P Elder Journal: Ann Epidemiol Date: 2010-08 Impact factor: 3.797
Authors: Alain G Bertoni; Jeanne M Clark; Patricia Feeney; Susan Z Yanovski; John Bantle; Brenda Montgomery; Monika M Safford; William H Herman; Steven Haffner Journal: J Diabetes Complications Date: 2008 Jan-Feb Impact factor: 2.852
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Sarah Stark Casagrande; Judith E Fradkin; Sharon H Saydah; Keith F Rust; Catherine C Cowie Journal: Diabetes Care Date: 2013-02-15 Impact factor: 19.112
Authors: Kelly J Hunt; Melanie Davis; John Pearce; John Bian; Mark F Guagliardo; Ernest Moy; R Neal Axon; Brian Neelon Journal: Diabetes Care Date: 2020-08-07 Impact factor: 19.112
Authors: Taylor L Clark; Linda Gallo; Johanna A Euyoque; Athena Philis-Tsimikas; Addie Fortmann Journal: Diabetes Educ Date: 2020-03-31 Impact factor: 2.140
Authors: Fang Bai; Jingsong Chen; Dilip Pandey; Ramon Durazo-Arvizu; Gregory A Talavera; Matthew A Allison; Krista M Perreira; Neil Schneiderman; Melanie W Sutherland; Jianwen Cai; Martha L Daviglus; Fernando D Testai Journal: Stroke Date: 2021-03-04 Impact factor: 7.914
Authors: Gregory A Talavera; Sheila F Castañeda; Paulina M Mendoza; Maria Lopez-Gurrola; Scott Roesch; Margaret S Pichardo; Melawhy L Garcia; Fatima Muñoz; Linda C Gallo Journal: Transl Behav Med Date: 2021-09-15 Impact factor: 3.626
Authors: Namino M Glantz; Jessikah M Morales; Wendy C Bevier; Arianna Larez; Charis B Hoppe; Ian Duncan; Andrew Mackenzie; David Kerr Journal: Health Equity Date: 2020-05-04
Authors: Addie L Fortmann; Athena Philis-Tsimikas; Johanna A Euyoque; Taylor L Clark; Daniela G Vital; Haley Sandoval; Julia I Bravin; Kimberly L Savin; Jennifer A Jones; Scott Roesch; Todd Gilmer; Thomas Bodenheimer; James Schultz; Linda C Gallo Journal: Contemp Clin Trials Date: 2020-10-11 Impact factor: 2.226